[1]Catalano V, Labianca R, Beretta GD, et al.Gastric cancer[J].Crit Rev Oncol Hematol, 2009, 71(2):127-164
[2]Pasini F, Fraccon AP, DE Manzoni G.The role of chemotherapy in metastatic gastric cancer[J].Anticancer Res, 2011, 31(10):3543-3554
[3]American Cancer Society, Survival Rates for Stomach Cancer by Stage, 2013, (accessed 05.09.13)
[4]Gschwind A, Fischer OM, Ullrich A.The discoveryof receptor tyrosine kinases: targets for cancer therapy[J].Nat RevCancer, 2004, 4(5):361-370
[5]Shepard HM, Brdlik CM, Schreiber H.Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family[J].J Clin Invest, 2008, 118(11):3574-3581
[6]Milanezi F, Carvalho S, Schnfitt FC.EGFRHER2 in breast cancer: a biological approach for molecular diagnosis and therapy[J].Expe Rev Mol Diagu, 2008, 8(4):417-437
[7]Rubin I, Yarden Y.The basic biology of HER2 [J].Ann Oncol, 2001, 12(suppl 1):3-8
[8]Sakai K, Mori S, Kawamoto T, et al.Expression of epidermal growth factor receptors on human gastric epithelia and gastric carcinomas[J].Natl Cancer Inst, 1986, 77(5):1047-1052
[9]Meza-Junco J, Au HJ, sawyer MB.Trastuzumab for gastric cancer[J].Expert Opin Biol Ther, 2009, 9(12):1543-1551
[10]Grabsh H, Sivakumar S, Gray S, et al.Her2 erpression in gastric cancer rare,heterogeneous and of no prognostic value-conclusions from 924 cases of two independent case seris[J].Cell Oncol, 2010, 32(1):57-65
[11]Bang YJ, Cutsem EV, Feyereislova A, et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of Her2 positive advanced gastric or gastroesophageal junction cancer (ToGA):a phase 3,open-lable,randomized controlled trial[J].Lancet, 2010, 376(9742):687-697
[12]Matsubara J, Yamada Y, Hirashima Y, et al.Impact of insulin like growth factor type1 receptor,epidermal growth factor receptor,and Her2 expressions on outcomes of patients with gastric cancer[J].Clin Cancer Res, 2008, 14(10):3022-3029
[13]Yan B, Yau EX, Bte Omar SS, et al.A study of HER2 gene ampli?cation and protein expression in gastric cancer[J].J Clin Pathol, 2010, 63(9):839-842
[14]Kim KC, Koh YW, Chang HM, et al.Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1414 cases of whole-tissue sections and 595 cases of tissue microarrays[J].Ann Surg Oncol, 2011, 18(10):2833-2840
[15]Im SA, Kim JW, Kim JS, et al.Clinicopathologic characteristics of patients with stage IIIIV (M(0)) advanced gastric cancer,according to HER2 status assessed by immunohistochemistry and ?uorescence in situ hybridization[J].Diagn Mol Pathol, 2011, 20(2):94-100
[16]Kunz PL, Mojtahed A, Fisher GA, et al.HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis with Proposed Approach to HER2 Assessment[J].Appl Immunohistochem Mol Morphol, 2012, 20(1):13-24
[17]Wang YY, Ye ZY, Li L, et al.ADAM 10 is associated with gastric cancer progression and prognosis of patients[J].J Surg Oncol, 2011, 103(2):116-123
[18]Hofmann M, Stoss O, Shi D, et al.Assessment of a HER2 scoring system for gastric cancer: results from a validation study[J].Histopathology, 2008, 52(7):797-805
[19]Yonemura Y, Ninomiya I, Yamaguchi A, et al.Evaluation of immunoreactivity for erbB-2 protein as a marker of poor shortterm prognosis in gastric cancer[J].Cancer Res, 1991, 51(3):1034-1038
[20]Park DI, Yun JW, Park JH, et al.HER-2neu amplification is an independent prognostic factor in gastric cancer[J].Dig Dis Sci, 2006, 51(8):1371-1379
[21]Barros-Silva JD, Leitao D, Afonso L, et al.Association of ERBB2 gene status with histopathological parameters and disease specific survival in gastric carcinoma patients[J].Br J Cancer, 2009, 100(3):487-493
[22]Grabsch H, Sivakumar S, Gray S, et al.HER2 expression in gastric cancer: rare,heterogeneous and of no prognostic value –conclusions from 924 cases of two independent case series[J].Cell Oncol, 2010, 32(1):57-65
[23]Wagner AD, Unverzagt S, Grothe W, et al.Chemotherapy for advanced gastric cancer[J]. Cochrane Database Syst Rev, 2010, (3):CD004064.
[24]Wagner AD, Grothe W, Haerting J, et al.Chemotherapy in advanced gastric cancer: a systematic review and meta analysis based on aggregate data[J].J Clin Oncol, 2006, 24(18):2903-2909
[25]Van Cutsem E, Moiseyenko VM, Tjulandin S, et al.Phase III study of docetaxel and cisplatin plus ?uorouracil compared with cisplatin and ?uorouracil as ?rst-line therapy for advanced gastric cancer: a report of the V325 study group[J].J Clin Oncol, 2006, 24(31):4991-4997
[26]Lordick F, Lorenzen S, Yamada Y, et al.Optimal chemotherapy for advanced gastric cancer: is there a global consensus?[J].[J].Gastric Cancer, 2014, 17(2):213-215
[27]Cunningham D, Starling N, Rao S, et al.Capecitabine and oxaliplatin for advanced esophagogastric cancer[J].New Engl J Med, 2008, 358(1):36-46
[28]Power DG, Kelsen DP, Shah MA.Advanced gastric cancer–slow but steady progress[J].Cancer Treat Rev, 2010, 36(5):384-392
[29]Bang YJ, Van Cutsem E, Feyereislova A, et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2 positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3,open-label,randomised controlled trial[J].Lancet, 2010, 376(9742):687-697
[30]Power DG, Kelsen DP, Shah MA.Advanced gastric cancer–slow but steady progress[J].Cancer Treat Rev, 2010, 36(5):384-392
[31]Dai GH, Shi Y, Chen L, et al.Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression[J].Hepatogastroenterology, 2012, 59(120):2439-2444
[32]Cunningham D, Allum WH, Stenning SP, et al.Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J].New Engl J Med, 2006, 355(1):11-20
[33]Rivera F, Jiménez P, Garcia Alfonso P, et al.NeoHx study: perioperative treatment with trastuzumab in combination with capecitabine and oxaliplatin (XELOX-T) in patients with HER2 resectable stomach or esophagogastric junction (EGJ) adenocarcinoma-R0 resection, pCR, and toxicity analysis[J].J Clin Oncol, 2013, 31(suppl):4098-4098
[34]Iqbal S, Goldman B, Fenoglio-Preiser CM, et al.Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer[J].Ann Oncol, 2011, 22(12):2610-2615
[35]Chen CT, Kim H, Liska D, et al.MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells[J].Mol Cancer Ther, 2012, 11(3):660-669
[36]Oshima Y, Tanaka H, Murakami H, et al.Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines[J].Gastric Cancer, 2014, 17(3):450-462